[1] 中华医学会肝病学分会,中华医学会感染病学分会. 丙型肝炎防治指南(2015更新版). 临床肝胆病杂志, 2015, 31: 1961-1979.
[2] 邹琳,佘会元. 丙型肝炎的治疗及进展. 肝脏, 2017, 22: 950-953.
[3] Falade-Nwulia O, Suarez-Cuervo C, Nelson DR, et al. Oral direct-acting agent therapy for hepatitis C virus infection: a systematic review. Ann Intern Med, 2017,166:637-648.
[4] Reig M, Mariño Z, Perelló C, et al. Unexpected high rate of early tumor recurrence in patients with HCV-related HCC undergoing interferon-free therapy. J Hepatol, 2016, 65: 719-726.
[5] Cardoso H, Vale AM, Rodrigues S, et al. High incidence of hepatocellular carcinoma following successful interferon-free antiviral therapy for hepatitis C associated cirrhosis. J Hepatol, 2016, 65: 1070-1071.
[6] Zhu AX, Duda DG, Sahani DV, et al. HCC and angiogenesis: possible targets and future directions. Nat Rev Clin Oncol, 2011, 8: 292-301.
[7] Nault JC, Colombo M. Hepatocellular carcinoma and direct acting antiviral treatments: Controversy after the revolution. J Hepatol, 2016, 65: 663-665. |
